Tanvex BioPharma, Inc. (TPE:6541)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
63.60
+0.60 (0.95%)
Apr 1, 2025, 1:35 PM CST
30.60%
Market Cap 15.15B
Revenue (ttm) 34.68M
Net Income (ttm) -1.38B
Shares Out 238.16M
EPS (ttm) -8.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 181,506
Average Volume 391,341
Open 63.30
Previous Close 63.00
Day's Range 63.30 - 64.70
52-Week Range 35.05 - 82.00
Beta 0.48
RSI 30.96
Earnings Date Mar 7, 2025

About Tanvex BioPharma

Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company’s products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. T... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 139
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6541
Full Company Profile

Financial Performance

In 2024, Tanvex BioPharma's revenue was 34.68 million, a decrease of -43.53% compared to the previous year's 61.41 million. Losses were -1.38 billion, -35.35% less than in 2023.

Financial Statements

News

There is no news available yet.